Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,740 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 1,740 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.89, for a total value of $266,028.60. Following the transaction, the insider now directly owns 18,202 shares in the company, valued at approximately $2,782,903.78. This represents a 8.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences Stock Up 1.5 %

Shares of Neurocrine Biosciences stock traded up $2.32 during trading on Tuesday, hitting $152.42. 814,308 shares of the company were exchanged, compared to its average volume of 950,096. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The stock has a market capitalization of $15.43 billion, a price-to-earnings ratio of 40.86 and a beta of 0.33. The firm has a 50 day moving average price of $137.92 and a 200 day moving average price of $131.51.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NBIX shares. Barclays raised their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Wedbush reaffirmed an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $166.85.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $25,000. Brooklyn Investment Group raised its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the last quarter. Blue Trust Inc. raised its holdings in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. R Squared Ltd acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $61,000. Finally, UMB Bank n.a. raised its holdings in Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after acquiring an additional 309 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.